Dover has entered into a definitive agreement to accumulate Malema Engineering Corp, a US designer and producer of high-precision, mission-critical flow-measurement and management devices for the biopharmaceutical, semiconductor and industrial sectors.
Image: dizain/Adobe Stock.
Malema’s products will broaden Dover’s biopharma single-use manufacturing offering, which already consists of Quattroflow pumps, CPC connectors, and em-tec flowmeters.
Based in เกจวัดแรงดันน้ำ10บาร์ , Florida, and with services in San Jose, California, Singapore, South Korea and India, Malema expects to generate roughly US$40 million–45 million in income in the course of the full year 2022.
When the deal closes, Malema will become a half of the PSG enterprise unit inside Dover’s Pumps & Process Solutions phase.
“We see an incredible long-term growth opportunity in the bioprocessing business driven by a strong and rising pipeline of effective novel biologic medicine, biosimilars, protein therapies, non-COVID mRNA vaccines, in addition to budding cell & gene therapies,” says PSG’s president Karl Buscher. “Additionally, the rising adoption of more efficient single-use manufacturing processes supports a strong outlook for our offerings of single-use components to end-customers. We believe that pairing Malema’s technology with our existing portfolio of single-use pumps for biopharma processing will greatly improve the accuracy and worth proposition of our options to our clients.”
“We are methodically building out our biopharma platform by way of proactive capacity additions, new product growth, and opportunistic acquisitions of highly-attractive niche part technologies,” stated Richard Tobin, president and CEO of Dover. “Malema represents a strategic and highly-complementary flow-control and sensing expertise and further strengthens our sensor portfolio with new proprietary know-how. In addition to attractive biopharma purposes, we expect strong development within the semiconductor area on the capability growth and re-shoring tailwinds.”
Share